Publicaties
1. Vasen HFA, Sindram JW, Struyvenberg A. Hemolytische anemie gecombineerd met ernstige levermetastasen als eerste teken van de ziekte van Wilson. Ned Tijdschr geneesk 1982; 126: 2142-44
2. Lips CJM, Vasen HFA, Lamers CBHW. Multiple Endocrine Neoplasia syndromes. CRC Crit. Rev Oncol Hematol 1984; 2: 117-184
3. Brouwers-Smalbraak GJ, Vasen HFA, Struyvenberg A, Nieuwenhuyzen Kruseman AC, Helsloot MH en Lips CJM Multiple Endocrine Neoplasia type 2A (MEN-2A): natural history, screening and central registration. Neth J Med 1986; 29: 111-117
4. Vasen HFA et al. MEN-2 syndrome. The value of screening and central registration; A study of six kindreds in the Netherlands. Henry Ford Hosp Med J 1987; 35; 101-103
5. Vasen HFA et al. Multiple Endocrine Neoplasia Syndrome type 2: The value of screening and central registration. A study of 15 kindreds in the Netherlands. Am J Med 1987; 83; 847-852
6. Vasen HFA, Griffioen G, Lips CJM, van Slooten EA. De waarde van screening en landelijke registratie van erfelijke tumoren. Ned Tijdschr Geneeskunde 1988; 132; 1609-1612
7. Vasen HFA, Griffioen G, Pena AS. Familial adenomatous polyposis: the value of central registration. J of Clinical Nutrition and Gastroenterology 1988; 3: 83-84
8. Vasen HFA, Bergman W, van Haeringen A, Scheffer E, van Slooten EA. The familial dysplastic nevus syndrome: natural history and the impact of screening on prognosis: A study of nine families in the Netherlands. Eur J Cancer Clin Oncol 1989; 25: 337-341
9. Vasen HFA, den Hartog Jager FCA, Menko FH, Nagengast FM. Screening for hereditary non-polyposis colorectal cancer. A study of twenty-two kindreds in the Netherlands. Am J Med 1989; 86: 278-281
10. Vasen HFA, Lamers CBHW, Lips CJM. Screening for the multiple endocrine neoplasia syndrome type 1. A study of 11 kindreds in the Netherlands. Arch Intern Med 1989; 149: 2717-2722
11. Griffioen G, Vasen HFA, Tops CMJ, Breukel C, Verspaget HW, den Hartog Jager FCA, Meera Khan P, Lamers CBHW.. Preclinical detection of familial adenomatous polyposis: Fact or fancy? Scan J Gastroenterol 1989; 24 (Suppl. 171): 38-45
12. Meera Khan P, Tops CMJ, Breukel C, Wijnen JTh, van de Klift H, vd Broek MH, Oldenburg M, vd Bos J, van Leeuwen-Cornelisse ISJ, Vasen HFA, Griffioen G, Lamers CBHW, Dietzsch E. Further evidence for loose linkage between APC and D5S6 (probe M4) in the Dutch polyposis families. Cytogenet Cell Genet 1989; 51: 1043
13. Tops CMJ, Breukel C, Wijnen JTh, van de Klift H, van de Broek MH, Oldenburg M, vd Bos J, van Leeuwen-Cornelisse ISJ, Vasen HFA, Griffioen G, Lamers CBHW, Meera Khan P. Linkage relationships between APC, D5S37 (probe Pi227) and D5S71 (probe C11p11) in the Dutch polyposis families. Cytogenet Cell Genet 1989; 51: 1092
14. Tops CMJ, Griffioen G, Vasen HFA, Breukel C, Wijnen JTh, van Leeuwen-Cornelisse ISJ, den Hartog Jager FCA, Nagengast FM, Lamers CBHW, Meera Khan P. Presymptomatic diagnosis of familial adenomatous polyposis by bridging DNA markers. Lancet 1989; 1361-1363
15. Jadoul M, Leo JR, Berends MJH, Ooms ECM, Buurke EJ, Vasen HFA, Seelen PJ, Lips CJM. Pheochromocytoma-induced hypertensive encephalopathy revealing MEN-IIa syndrome in a 13-year old boy Implications for screening procedures and surgery. Hormone and Metabolic Research Supplement Series, 1989; 21: 46-49
16. Vasen HFA, Offerhaus GJA, den Hartog Jager FCA, Menko FH, Nagengast FM, Griffioen G, van Hogezand RB, Heintz APM. The tumour spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in the Netherlands. Int J Cancer 1990; 46: 31-34
17. Muller HJ, Vasen HFA. Prevention familierer Tumor Krankheiten durch genetische Beratung und Fruhdiagnostik. Schweiz Med Wschrift, Heft 40, 1990
18. Vasen HFA, Griffioen G, Offerhaus GJA, den Hartog Jager FCA, van Leeuwen-Cornelisse ISJ, Meera Khan P, Lamers CBHW, van Slooten EA. The value of screening and central registration of families with familial adenomatous polyposis A study of 82 families in the Netherlands. Dis Colon Rectum 1990; 33: 227-230
19. Vasen HFA, Griffioen G, Lips CJM, Struyvenberg A, van Slooten EA. Screening of families predisposed to cancer development in the Netherlands. Anticancer Res 1990; 10: 555-564
20. Tops CMJ, Breukel, C, van der Klift HM, van Leeuwen-Cornelisse ISJ, Wijnen JT, Griffioen G, Vasen HFA, den Hartog Jager FCA, Nagengast FM, Lamers CBHW, Meera Khan P. A new deletion polymorphism at D5S71 raises the linkage information on adenomatous polyposis coli: implications for presymptomatic diagnosis. Hum Genet 1991; 86: 365-368
21. Jadoul M, Koppeschaar HPF, Bax MA, Mali WPTh, Wit JM, Huber J, Vasen HFA, van der Sluys Veer J, Struyvenberg A, Lips CJM. Insulinomas in MEN-I patients: early detection and treatment of insulinomas in patients with the multiple endocrine neoplasia syndrome type-I. Neth J Med, 1990; 37: 95-102
22. Meera Khan P, van den Broek MH, Tops CMJ, Vasen HFA, Griffioen G, den Hartog Jager FCA. Clinical versus genetic heterogeneity of hereditary colorectal cancer; implications for presymptomatic diagnosis. Anticancer Res 1990; 10: 1459-1460
23. Meera Khan P, Tops CMJ, Breukel C, Wijnen JTh, van der Klift HM, van Leeuwen-Cornelisse ISJ, Vasen HFA, Griffioen G, den Hartog Jager FCA, Lamers CBHW. Linkage studies on familial adenomatous polyposis (FAP) in the Netherlands. Int J Colorectal Dis 1990; 5: 56-57
24. Vasen HFA, Mecklin J-P, Meera Khan P, Lynch HT. Hereditary non-polyposis colorectal cancer. Lancet 1991; 338: 877
25. Vasen HFA, Mecklin J-P, Meera Khan P, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 224-5
26. Vasen HFA, Muller HJ. DNA-onderzoek in families met erfelijke vormen van kanker. Ned Tijdschr Geneeskd 1991; 135: 1620-3
27. Vasen HFA, Feltz M van der, Raue F, Nieuwenhuyzen Kruseman A, Koppeschaar HPF, Pieters G, Seif FJ, Blum WF, Lips CJM. The natural course of multiple endocrine neoplasia type IIb; A study of 18 cases. Arch Intern Med, 1992;.152:1250-1252
28. Tops CMJ, Vasen HFA, van Berge Henegouwen G, Simoons PP, van de Klift HM, van Leeuwen-Cornelisse ISJ, Breukel C, Fodde R, den Hartog Jager FCA, Nagengast FM, Griffioen G, Meera Khan P. Genetic evidence that Turcot syndrome is not allelic to familial adenomatous polyposis. Am J Med Genet 1992; 43: 888-893
29. Fodde R, van der Luijt R, Wijnen J, Tops C, van der Klift H, van Leeuwen-Cornelisse I, Griffioen G, Vasen HFA, Meera Khan P. Eight novel inactivating germ line mutations at the APC gene identified by denaturing gradient gel electrophoresis. Genomics 1992; 13: 1162-1168
30. Calmettes C, Ponder BAJ, Fischer JA, Raue F, and the members (ao HFA Vasen) of the European Community Concerted Action: Medullary Thyroid Carcinoma. Early diagnosis of the multiple endocrine neoplasia type 2 syndrome, consensus statement. Eur J Clin Inves 1992;22:755-760.
31. Vasen HFA, Griffioen G, Tops CJM, van Haeringen A, Nagengast FM, van Leeuwen-Cornelisse ISJ, Meera Khan P, van Slooten EA. Familial adenomatous polyposis and its clinical surveillance. Neth J Med, 1993;42:105-108
32. Bülow S, Burn J, Neale K Northover J, Vasen H. The establishment of a polyposis register. Int J Colorectal Dis, 1993;8:34-38
33. Vasen HFA, Mecklin J-P, Watson P, Utsunomiya J, Bertario L, Lynch P, Svendsen LB, Cristofaro G, Møller HJ, Meera Khan P, Lynch HT (The International Collaborative Group on HNPCC). Surveillance in Hereditary Non-Polyposis Colorectal Cancer: An international cooperative study on 165 families. Dis Colon Rectum 1993;1:1-4
34. Devilee P Cornelis RS, Bootsma A, Bardoel A, van Vliet M, van Leeuwen I, Cleton F, de Klein A, Lindhout D, Vasen HFA, Cornelisse CJ, Meera Khan P. Linkage to markers for the chromosome region 17q12-q21 in 13 Dutch breast cancer kindreds. Am J Hum Genet 1993;52:730-735
35. Vasen HFA, Beex LVAM, Cleton FJ, Collette HJA, van Dongen JA, van Leeuwen FE, Crommelin MA, Meera Khan P. Clinical heterogeneity of hereditary breast cancer and its impact on screening protocols: The Dutch experience on 24 families under surveillance. Eur J Cancer 1993;29A:1111-1114
36. Tops CMJ, Van der Klift HM, Van der Luijt RB, Griffioen G, Taal BG, Vasen HFA, Meera Khan P. Non-Allelic Heterogeneity of Familial Adenomatous Polyposis. Am J Med Gen 1993;47-563-567
37. Vasen HFA. Screening for Multiple Endocrine Neoplasia Type 1. Acta Chirurgica 1993;25:57-58
38. Vasen HFA, Devilee P. Screening van families met een erfelijke predispositie voor mammacarcinoom. Ned Tijdschr Geneeskunde 1993;137:2350-2354
39. Vasen HFA. Periodiek onderzoek van families met hereditair nonpolyposis colorectaal carcinoom in Nederland: een studie van 41 families. Ned Tijdschr Geneeskd 1994;138:77-81
40. Vasen HFA. Vroege diagnostiek van erfelijke tumoren. Tijdschr v Huisartsengeneeskunde 1994;11:211-216
41. Vasen HFA. Screening in Breast Cancer Families: Is it Useful? Annals Medicine 1994;26:185-190
42. Watson P, Vasen HFA, Mecklin JP, Lynch HT. The risk of endometrial cancer in Hereditary Nonpolyposis Colorectal Cancer. Am J Med, 1994;96:516-20
43. Van der Luijt R, Meera Khan P, Vasen H, Van Leeuwen C, Tops C, Roest P, den Dunnen J, Fodde R. Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. Genomics 1994;20:1-4
44. Vasen HFA, Vermey A. Hereditary Medullary Thyroid Carcinoma. Cancer Detect Prev 1995;19:143-150
45. Vasen HFA, Taal BG, Griffioen G, Nagengast FM, Cats A, Menko FH, Oskam W, Kleibeuker JH, Offerhaus GJA, Meera Khan P. Clinical heterogeneity of familial colorectal cancer and its influence on screening protocols. Gut 1994;35:1262-1266
46. Vasen HFA. Inherited forms of colorectal, breast and ovarian cancer: guidelines for surveillance. Surg Oncol Clin North America 1994; 3:501-521
47. Mecklin J-P, Svendsen LB, Peltomaki P, Vasen HFA. Hereditary Nonpolyposis Colorectal Cancer. Scand J Gastroenterology 1994:29:673-677
48. Vasen, HFA. What is hereditary nonpolyposis colorectal cancer (HNPCC)?. Anticancer Research 1994;14:1613-1616
49. Vasen HFA, Mecklin J-P, Meera Khan P, Lynch HT. The International Collaborative Group on HNPCC. Anticancer Research 1994;14:1661-1664
50. Vasen HFA, Watson P, Mecklin J-P, Jass JR, Green JS, Nomizu T, Møller H, Lynch HT. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Research 1994;14:1675-1678
51. Vasen HFA, van Erpecum KJ, Roelfsema F, Raue F, Koppeschaar H, Griffioen G, van Berge Henegouwen GP. Increased prevalence of colonic adenomas in patients with acromegaly. Eur J Endocrinol 1994;131:235-237
52. Menko FH, Verheijen RHM, Everhardt E, Louwe LA, Band SC, Felt-Bersma RJF, Vasen HFA, Meera Khan P. Endometrial cancer in four sisters: Report of a kindred with presumed cancer family syndrome. Gynaecologic Oncology 1994;54,171-174
53. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, and the Beast Cancer Linkage Consortium (ao HFA Vasen). Risk of cancer in BRCA1-mutation carriers. Lancet 1994;343:692-695
54. Modigliani E, Vasen HF, Raue F, Dralle H, Frilling A, Gheri RG, Brandi ML, Limbert E, Niederle B, Forgas L, Giu M, Møller P, Feingold N, Calmettes C and the EuroMEN study group. Pheochromocytoma in multiple endocrine neooplasia type 2 (MEN 2): European study of 300 cases. J Intern Med 1995:238;363-367
55. Dralle H Scheumann GFW, Proye C, Bacourt F, Frilling A, Limbert F, Gheri G, Henry JF, Berer M, Niederle B, Vasen HFA. The value of lymph node dissection in hereditary MTC, a retrospective European multicenter study. J Intern Med 1995:238;3 57-62
56. Vasen HFA, J-P Mecklin, Meera Khan P, Lynch HT. Screening for hereditary colorectal cancer. Lancet 1994;344:877
57. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium (ao. Vasen HFA). Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995;56:265-271
58. Wijnen J, Vasen H, Meera Khan P, et al. Seven new mutations in hMSH2 and HNPCC gene, identified by denaturing gradient-gel electrophoresis. Am J Hum Genet 1995;56:1060-1066
59. Hogervorst FBL, Cornelis RS, Bout M, van Vliet M, Oosterwijk JC, Olmer R, Bakker B, Klijn JGM, Vasen HFA, Meijers-Heijboer H, Menko FH, Cornelisse CJ, den Dunnen JT, Devilee PD, van Ommen GJB. Rapid detection of BRCA1 mutations by the protein truncation test. Nature Genetics 1995;10:208-212
60. Cornelis RS, Vasen HFA, Meijers-Heijboer H, et al. Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer. Hum Genet 1995;95:539-544
61. van der Luijt RB, Tops CMJ, Meera Khan P, van der Klift HM, Breukel C, van Leeuwen-Cornelisse ISJ, Dauwerse HG, Beverstock GC, van Noort E, Snel P, Slors FJM, Vasen HFA, Fodde R. Molecular, cytogenetic, and phenotypic studies of a constitutional reciprocal translocation t(5;10)(q22;q25) responsible for Familial Adenomatous Polyposis in a Dutch pedigree. Genes Chromosomes Cancer 1995;1 3:192-202
62. Vasen HFA, Taal BG, Nagengast FM, Griffioen G, Menko FH, Kleibeuker JH, Offerhaus GJA,. Meera Khan P. Hereditary nonpolyposis colorectal cancer: Results of long-term surveillance in 50 families. Eur J Cancer 1995; 31A: 1145-1148
63. Burn J, Chapman PD, Bertario L, Bishop DT, Bülow S, Cummings J, Mathers J, Phillips R, and Vasen H. A European Double-blind Trial of Aspirin and Resistant Starch in Familial Adenomatous Polyposis: The CAPP study Eur J Cancer 1995; 31A
64. Bülow S, Alm T, Fausa O, Hultcrantz R, J?rvinen H, Vasen H. Duodenal adenomatosis in familial adenomatous polyposis DAF Project Group. Int J Colorectal Dis 1995;10:43-46
65. Vasen HFA, Nagengast FM, Meera Khan P. Interval cancers in hereditary non-polyposis colorectal cancer (Lynch syndrome). Lancet 1995;345:1183-1184
66. van der Luijt RB, Vasen HFA, Tops CMJ, Breukel C, Fodde R, Meera Khan P. APC mutation in the alternatively spliced region of exon 9 assocated with late onset familial adenomatous polyposis. Hum Genet 1995;96:705-710
67. Vasen HFA, Sanders EACM, Taal BG, Nagengast FM, Griffoen G, Menko FM, Kleibeuker JH, Houwing-Duistermaat JJ, Meera Khan P. The risk of brain tumours in Hereditary Non-Polyposis Colorectal Cancer (HNPCC). Int J Cancer 1996;65:422-425
68. Vasen HFA, Wijnen J, Meera Khan P, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-1027
69. Lynch HT, Drouhard T, Vasen HFA, et al. Genetic counseling in a Navajo HNPCC kindred. Cancer 1996;77:30-35
70. Vasen HFA. Vroege diagnostiek van erfelijke tumoren. Tijdschr v Huisartsgeneeskunde 1996; 1: 16-21
71. Menko FH, Nooy MA, Vasen HFA. Erfelijke mutaties in het p-53 tumor suppressor-gen: betekenis voor de klinische praktijk. Ned Tijdschr Geneeskunde 1996;26: 1347-1350
72. Vasen HFA. Erfelijke colontumoren Bijblijven 1996; 12: 58-65
73. Kiemeney LALM, Witjes JA, Hendrikx AJM en Vasen HFA. Erfelijk prostaatcarcinoom. Ned Tijdschr Geneeskunde 1996;140:1068-1072
74. Wijnen J, Meera Khan P, Vasen H, Menko FH, van der Klift H, van den Broek M, van Leeuwen-Cornelisse I, Nagengast F, Meijers-Heijboer A, Lindhout D, Griffioen G, Cats A, Kleibeuker J, Varesco L, Bertario L, Bisgaard ML, Mohr J, Kolodner R, and Fodde R. Majority of hMLH1 mutations responsible for hereditary nonpolyposis colorectal cancer (HNPCC) cluster at the exonic region 15-16. Am J Hum Genet 1995;58:300-7
75. Wert GMWR, namens de werkgroep erfelijk mammacarcinoom. Predictief testen op p53-mutaties: ethische overwegingen. Ned Tijdschr Geneeskunde, 1996; 140: 1350-1353
76. Stigt JA, Vasen HFA, van der Linde K, van Vliet ACM. Thyroid carcinoma as first manifestation of familial adenomatous polyosis. Neth J Med 1996;49:116-118
77. Vasen HFA. Erfelijk en familair colorectaal carcinoom: richtlijnen voor beleid. Patient Care 1996,23: 28-34
78. Menko FH, Wijnen JTh, Meera Khan P, Vasen HFA, Oosterwijk MH. Genetic Counseling in Hereditary Nonpolyposis Colorectal Cancer. Oncology 1996;10:71-76
79. Vasen HFA, van der Luijt RB, Slors JFM, Buskens E, de Ruiter P, Baeten CGM, Schouten WR, Oostvogel HJM, Kuijpers JHC, Tops CMJ, Meera Khan P. Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 1996;348:433-435
80. Peelen T, Cornelis RS, van Vliet M, Petrij-Bosch A, Cleton-Jansen AM, Meijers-Heijboer H, Klijn JGM, Vasen HFA, Cornelisse CJ, Devilee P. The majority of 22 Dutch high risk breast cancer families are due to either BRCA1 or BRCA2. Eur J Hum Genet 1996;4:225-230
81. van der Luijt RB, Meera Khan P, Vasen HFA, Breukel C, Tops CMJ, Scott RJ, Fodde R. Germline mutations in the 3' part of APC exon 15 do not result in truncated proteins and are associated with attenuated adenomatous polyposis coli. Hum Genet 1996; 98:727-34
82. Breast Cancer Linkage Consortium (ao Vasen HFA). Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 1997; 349: 1505-1510
83. Peltomaki P, Vasen HFA, and the International Collaborative Group on HNPCC. Mutations predisposing to Hereditary Nonpolyposis Colorectal Cancer: Database and results of a collaborative study. Gastroenterology 1997;113-1146-1158
84. Voskuil DW,Kampman E, Grubben MJ, et al. Meat Consumption and preparation, and genetic susceptibility in relation to colorectal adenomas. Cancer Letters 1997; 114: 309-311
85. van de Luijt RB, Khan PM, Vasen HF, et al. Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis. Human Mutation 1997;9:7-16
86. Vasen HFA, van Ballegooijen M, Buskens E, et al. Cost-effectiveness analysis of colorectal cancer screening in hereditary nonpolyposis colorectal cancer. Cancer 1998, 82:1632-7
87. Peelen T, van Vliet M, Petrij-Bosch A, et al. (a.o. Vasen HFA) A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 1997;60:1041-1049
88. Bülow C, Bülow S, and the Leeds Castle Polyposis Group (a.o. Vasen HFA). Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? Int J Colorecal Disease 1997;12:240-2
89. Vasen HFA, Bülow S, Myrhoj T, et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut 1997;30:716-719
90. Cornelis RS, van Vliet M, van de Vijver MJ, Vasen HFA, et al. Three germline mutations in the TP53 gene. Human mutations 1997;9:157-163
91. Devilee P, Hermans J, Eyfjord J, et al. (a.o. Vasen HFA) Loss of heterozygosity at 7q31 in breast cancer: results from an international collaborative study group. Genes Chromosomes Cancer 1997;18:193-199
92. Voskuil DW, Vasen HFA, Kampman E, et al. Colorectal Cancer risk in HNPCC families: development during lifetime and in successive generations. Int J Cancer 1997;72:205-209
93. Wijnen J, Meera Khan P, Vasen H, van der Klift H, Mulder A, van Leeuwen-Cornelisse I, Bakker B, Losekoot M, Møller, P, and Fodde R. Hereditary Nonpolyposis Colorectal Cancer families not complying with the Amsterdam criteria show extremely low frequency of mismatch-repair-gene mutations. Am J Hum Genet 1997;61:329-335
94. Rodriguez-Bigas MA, Vasen HFA, Mecklin JP, et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. Ann Surg 1997;2:202-207
95. Rodriguez-Bigas MA, Vasen HFA, Lynch HT, et al. Characteristics of small bowel cancer in hereditary nonpolyposis colorectal cancer (HNPCC). Cancer 1998, 83:240-4
16. Rodriguez-Bigas MA, Vasen HFA, O?Malley L, et al. Health, Life, and Disability Insurance in Hereditary Nonpolyposis Colorectal Cancer (HNPCC). Am J Hum Gen 1998; 62:736-7
97. van der Linde K, Vasen HFA, van Vliet ACM. Occurrence of thyroid carcinoma in Dutch patients with familial adenomatous polyposis. An epidemiologic study and report of new cases. Eur J Gastoenterol Hepatol 1998; 10:777-81
98. Petrij-Bosch A, Peelen T, van Vliet M, et al. (a.o. Vasen HFA) Large genomic founder deleti9ns in BRCA1 among Dutch breast cancer families. Nature Genetics 1997; 75: 62-74
99. Dudok de Wit AC, Tibben A, Duivenvoorden HJ, et al. (a.o. Vasen HFA) Predicting adaptation to presymptomatic DNA testing for late onset disorders, Who will experience distress? J Med Gen 1998; 35: 745-54
100. Griffioen G, Bus PJ, Vasen HFA, Verspaget HW, Lamers CB. Extracolonic manifestations of familial adenomatous polyposis: desmoid tumors and upeer gastrointestinal adenomas and carcinomas. Scand J Gastroenterology 1998; suppl 225:85-91
101. Sijmons RH, Kiemeney LALM, Witjes JA, Vasen HFA. Urinary tract cancer and hereditary non-polyposis colorectal cancer: risks and screening options. Comment in: J Urol 1998;160:466- 1999:161;926
102. Dudok de Wit AC, Tibben A, Duivenvoorden HJ, et al. (a.o. Vasen HFA) Distress in individuals facting predictive DNA testing for autosomal dominant inheritable late onset disorders; comparing questionnaire results with in depth interviews. Am J Med Genet, 1998; 75:62-74
103. Dudok de Wit AC, Tibben A, Duivenvoorden HJ, et al. (a.o. Vasen HFA) Psychological distress in applicants of predive DNA testing for autosomal dominant inheritable late onset disorders. J Med Genet 1997;34:382-391
104. Vasen HFA, van der Luyt RB, Tops C, Slors JFM. Molecular genetic tests in surgical management of familial adenomatous polyposis.(letter) Lancet 1998; 351
105. Ford D, Easton DF, Stratton M, et al (a.o. Vasen HFA). Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-89
106. Wijnen JTh, Vasen HFA, Meera Khan P et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Eng J Med 1998; 339: 511-518
107. Vasen HFA et all Current guidelines for management of families with hereditary breast-ovarian cancer syndrome: a survey among 16 European family cancer clinics. Eur J Cancer 1998; 34: 1922--26
108. Wijnen JTh, van der Klift H, Vasen HFA et al. MSH2 genomic deletions are a frequent cause of HNPCC. Nature Genetics 1998; 20: 326-28
109. Vasen HFA, Watson P, Mecklin J-P, Lynch HT and the ICG-HNPCC. New clinical criteria for Hereditary Nonpolyposis Colorectal Cancer (HNPCC, Lynch Syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 1999:116;1453-1456
110 Menko FH, Griffioen G, Wijnen J Th, Tops CMJ, Fodde R, Vasen HFA. Genetica van darmkanker. I. Non-polyposis- en polyposisvormen van erfelijke darmkanker. Ned Tijdschr Geneeskd 1999:143;1201-1206
111. Menko FH, Griffioen G, Wijnen J Th, Tops CMJ, Fodde R, Vasen HFA. Genetica van darmkanker. II. Erfelijke achtergrond van sporadische en familiaire darmkanker. Ned Tijdschr Geneeskd 1999:143;1207-1210
112. Vasen HFA, Nagengast FM, Griffioen G, Kleibeuker JH, Menko FH, Taal BG. Periodiek colonoscopisch onderzoek bij personen met een belaste familieanamnese voor colorectaal carcinoom. Ned Tijdschr Geneeskd 1999:143;1211-1214
113. Vasen HFA. Obituary P. Meera Khan (1935-1998). Journal of Genetics 1999:78;63-70
114. Park JG, Park YJ, Wijnen JTh, Vasen HFA. Gene-environment interaction in hereditary nonpolyposis colorectal cancer with implications for diagnosis and genetic testing. Int J Cancer 1999; 82: 516-9
115. Vasen HFA, Bülow S, and the Leeds Castle Polyposis Group. Guidelines for surveillance and management of familial adenomatous polyposis (FAP): a world wide survey among 41 registries. Colorectal Disease 1999:1;214-221
116. Vasen HFA, Wijnen J. Clinical implications of genetic testing of hereditary nonpolyposis colorectal cancer; Cytogenet Cell Genet 1999; 86: 136-9
117. Bus PJ, Verspaget HW, van Krieken HJM, de Roos, A, Keizer HJ, Bemelman WA, Vasen HFA, Lamers CBHW, Griffioen G. Treatment of mesenteric desmoid tumors with the anti-estrogenic agent Toremifene. Eur J Gastroenterology Hepatology 1999; 11: 1179-83
118. Taal BG, van Loon HJ, Kahn N, de Jong D, Vasen HFA, van 't Veer LJ. De rol van genetische factoren bij het ontstaan van maagcarcinoom. Ned Tijdschr Geneeskd 1999:143;342-346
119. Sijmons RH, Kiemeney LALM, Witjes JA, Vasen HFA. Urinary tract cancer and hereditary non-polyposis colorectal cancer: risks and screening options. J Urol 1998;160:466-470
120. Rodriguez-Bigas MA, Vasen HF, O'Malley L, Rosenblatt MJ, Farrell C, Weber TK, Petrelli NJ. Health life, and disability insurance and hereditary nonpolyposis colorectal cancer [letter]. Comment in: Am J Hum Genet 1999:64;736-737
121. Park JG, Vasen HF, Park KJ, Peltomaki P, Ponz de Leon M, Rodriguez-Bigas MA, Lubinski J, Beck NE, Bisgaard ML, Miyaki M, Wijnen JT, Baba S, Lynch HT. Suspected hereditary nonpolyposis colorectal cancer: International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) criteria and results of genetic diagnosis. Dis Colon Rectum 1999:42;715-716
122. Griffioen G, Vasen HFA, Verspaget HW, Lamers CBHW. Familial Adenomatous Polyposis: from bedside to bench and vice versa. A tribute to the somatic cell geneticist P. Meera Khan. Special issue in memory of prof.dr. P. Meera Khan. Cytogenet Cell Genet 1999; 86: 125-29
123. Van Duijvendijk P, Vasen HFA, Bertario L, Bülow S, Kuijpers HC, Schouten WR, Guillem JG, Taat CW, Slors FM. Cumulative risk of developing polyps or malignancy at the ileal pouch-anal anastomosis in patients with familial adenomatous polyposis. J Gastrointest Surg 1999:3;325-330
124. Van Duijvendijk P, Slors JFM, Taat CW, Oosterveld P, Vasen HFA. Functional outcome after colectomy and ileorectal anastomosis compared to proctocolectomy and ileal pouch-anal anastomois in familial adenomatous polyposis. Ann Surg 1999; 230: 648-54
125. Hodgson S, Milner B, Brown I, Beviacqua G, Chang-Claude J, Eccles D, Evans G, Gregory H, Møller P, Morrison P, Steel M, Stoppa-Lyonet D, Vasen HFA, Haites N. Cancer genetics services in Europa. Disease Markers 1999;15 :3-13
126. Steel M, Smyth E, Vasen HFA et al. Ethical, social and economic issues in familial breast cancer: a compilation of views from the E,C, Biomed II Demonstration project. Disease Markers 1999; 15: 125-131
127. Evans DGR, Anderson E, Lallo F, Vasen HFA, et al. Utilisation of prophylactic mastectomy in 10 European Centres. Disease Markers 1999; 15: 148-151
128. Morrison PJ, Steel CM, Vasen HFA, et al. Insurance implications for individuals with a high risk of breast and ovarian cancer in Europe. Disease Markers 1999; 15: 159-165
129. Møller P, Reis MM, Evans G, Vasen HFA, et al. Efficacy of early diagnosis and treatment in women with a family history of breast cancer. Disease Markers 1999; 15: 179-186
130. Møller P, Evans G, Haites N, Vasen HFA, et al. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on inherited breast cancer. Disease Markers 1999; 15: 207-211
131. Wijnen J, de leeuw W, Vasen HFA, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nature Genetics 1999; 23: 142-4
132. Van Duijvendijk P, Slors JFM, Taat CW, Oosterveld P, Sprangers MAG, Obertop H, Vasen HFA. Quality of life after total colectomy with ileorectal or proctocolectomy and ileoanal anastomosis for familial adenomatous polyposis, Br J Surg 2000;87:590-6
133. Vasen HFA. When should endoscopic screening in familial adenomatous polyposis be started? (letter) Gastroenterology 2000;118:808-9
134. Peelen T, et al (a.o. Vasen HFA). Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families Br J Cancer 2000;82:151-6
135. Brunner H, Vasen HFA. Erfelijke vormen van kanker en tumorsyndromen. Bijblijven 2000;16: 28-38
136. Sijmons RH, Hofstra RMW, Hollema H, Mensink R, van der Hout AH, Hoekstra HJ, Kleibeuker JH, Molenaar WM, Wijnen J, Vasen HFA, Buys CHCM. Malignant fibrous histiocytoma in a patient with hereditary non-polyposis colorectal cancer. Genes Chromosomes Cancer 2000; 29: 353-5
137. de Leeuw W, Wijnen JTh, Vasen HFA et al. Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis of endometrial carcinoma from hereditary nonpolyposis colorectal carcinoma. J Pathol 2000: 192: 328-35
138. Vasen HFA, Gruis NA, Frants, van der Velden PA, Hille ETM, Bergman W. The risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma (FAMMM) associated with a specific 19 bl deletion of P16 (P16 Leiden), Int J Cancer 2000; 87: 809-11
139. Vasen HFA. The clinical management of hereditary colorectal cancer syndromes. J Clin Oncol 2000; 18: 81s-92s
140. Bülow C, Vasen HFA, Jarvinen H, et al. Ileorectal anastomosis is appropriate in a subset of patients with familial adenomatous polyposis. Gastroenterology 2000; 119: 1454-60
141. Wijnen JTh, Morreau H, Vasen HFA. Van gen naar ziekte: van DNA-mismatch herstelgenen naar hereditair nonpolyposis colorectaal carcinoom, Ned Tijdsch Geneesk 2001, 145: 780-82
142. van der Luijt R, Tops C, Vasen HFA. Van gen naar ziekte: van APC-gen tot familaire adenomateuze polyposis. Ned Tijdsch Geneesk 2000; 144: 2007-9
143. Vasen HFA. Colorectal cancer and family history. Annales Chirurgiae et Gynaecologiae 2000; 89: 179-84
144. Peelen T, van Vliet M, Bosch A, Bignell A, Vasen HFA et al. Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer and linked to BRCA 1, fails to support a role for BRCA1 in colorectal tumorigenesis. Int J Cancer 2000; 88: 778-82
145. Voskuil D, Kampman E, van Geloof W, Grubben M, Kok F, van Muijen G, Nagengast F, Vasen H, van 't Veer P. No major difference in K-ras and p53 abnormalities in sporadic and hereditary non polyposis colorectal adenomas. Dig Dis Sciences 2000; 45: 2187-94
146. Vasen HFA, Duijvendijk van P, Buskens et al. Decision analysis in the surgical treatment of patients with familial adenomatous polyposis, GUT 2001; 49: 231-35
147. Hodgson SV, Haites NE, Caligo M, Chang-Claude J, Eccles D, Evans G, Møller P, Morrison P, Steel CM, Stoppa-Lyonnet D, Vasen HFA. A survey of the current clinical facilities for the management of familial cancer in Europe. Europe Union BIOMED II Demonstration Project: Familial Breast Cancer: Audit of a new development in medical practice in European centres. J Med Genet 2000; 37:605-7
148. Morrison PJ, Steel M, Nevin NC, et al. (a.o. Vasen HFA). Insurance considerations for individuals with a high risk of breast cancer in Europe: some recommendations. CME Journal of Gynecologic Oncology 2001, 272-7
149. Gregory H, Milner B, Haites NE, et al. (a.o. Vasen HFA). Current breast cancer screening services available throughout Europe to families at increased genetic risk for breast cancer. CME Journal of Gynecologic Oncology 2001, 248-53
150. Hodgson S, Milner B, Brown I, et al. (a.o. Vasen HFA). Clinical service development for familial breast cancer in European countries; the role and training of genetic counsellors in this service, and educational provision in cancer genetics. CME Journal of Gynecologic Oncology 2001, 261-8
151. Steel CM, Morrison PJ, Møller P, et al. (a.o. Vasen HFA). Familial breast cancer: some social, economic and ethical issues. CME Journal of Gynecologic Oncology 2001, 278-86
152. Møller P, Evans G, Haites NE, et al. (a.o. Vasen HFA). Women at risk for inherited breast or ovarian cancer: guidelines for follow up. CME Journal of Gynecologic Oncology 2001, 269-71
153. Wagner A, Hyndriks Y, Meijers-Heijboer EJ, et al. (a.o. Vasen HFA). Atypical HNPCC due to MSH germline mutations: analysis of a large Dutch pedigree. J Med Genet 2001, 38;318-322
154. Thompson D, Easton D, on behalf of the Breast Cancer Linkage Consortium (a.o. Vasen HFA). Variation in cancer risks by mutation position in BRCA2 mutation carriers. Am J Hum Genet 2001, in press
155. Vasen HFA, Stormorken A, Menko FH, et al. Carriers of MSH2 mutations have a higher risk of devloping cancer than MLH1 mutation carriers. A study of 101 families with hereditary nonpolyposis colorectal cancer (HNPCC), J Clin Oncol 2001;19: 4074-80
156. Voskuil D, Kampman E, Grubben M, Kok F, Nagengast F, Vasen H, van 't Veer P. Meat consumption and preparation in relation to sporadic and hereditary adenomas. 2000 submitted
157. Peelen T et al(a.o. Vasen HFA). Predicting the probability of detecting BRCA1 and BRCA2 mutations in 164 Dutch breast/ovarian cancer families. 2000 submitted
158. Dove-Edwin I, Boks D, Kenter G, Vasen HFA, Thomas H. The outcome of endometrial cancer surveillance by transvaginal ultrasound scan in women with hereditary nonpolyposis colorectal cancer and familial colorectal cancer, Cancer 2002; 94: 1708-12
159. Watson P, Butzow R, Lynch HT, Mecklin J-P, Jarvinen HJ, Vasen HFA, Madlenski L, Fidalgo P, Myrhoi T and the ICG-HNPCC. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer (HNPCC), Gynaecol Oncol 2001; 82: 223-4
160. Vasen HFA, Morreau H, Nortier JH. Is breast cancer part of the tumor spectrum in HNPCC. Am J Hum Genet 2001;68: 1533-1534
161. Hendriks YMC, Verhallen JTCM, van der Smagt JJ et al. (a.o.HFA Vasen). The Bannayan-Riley-Ruvalcaba Syndrome; increased risk for malignant tumours? Proposalfor a screening protocol. TIJDSCHRIFT
162. Van Ruth S, de Vos WH, van Laarhoven CJHM, Vasen HFA namens de landelijke werkgroep FAP.Frequentievan duodenum adenomen bij patienten met FAP. Ned Tijdschr Geneskd 2001; 145: 1744-48
163. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, Menko FH, Taal BG, Kleibeuker JH, Vasen HFA. Surveillance for hereditary non-polyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002; 45: 1588-94
164 Voskuil DW, Kampman E, Grubben MJ, Kok FJ, Nagengast FM, Vasen HF, van ‘t Veer P. Meat consumption and meat preparation in relation to colorectal adenomas among sporadic and HNPCC family patients in The Netherlands. Eur J Cancer 2002; 38: 2300-8
165. Wagner A, Tops C, Wijnen JT, et al (a.o. HFA Vasen). Genetic testing in hereditary non-polyposis colorectal cancer families with a MSH2, MLH1 or MSH6 mutation. J Med Genet 2002; 39: 833-7
166. Meulenbeld HJ, Verhage BA, Kil PJ, Kiemeney LA, Vasen HF. Karakterisering van families met hereditair prostaatcarcinoom in Nederland. Ned Tijdschr Geneeskd 2002; 146: 1938-42
167. Boks DE, Trujillo AP, Voogd AC, Morreau H, Kenter GG, Vasen HF. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002; 102:198-200
168. Moller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer2002: 101: 555-9
169. Pikaar A, Nortier JW, Griffioen G, Vasen HF. Desmoid tumors in patients with FAP. Ned Tijdschr Geneeskd. 2002; 146: 1355-9
170. Dove-Edwin I. Boks D. Goff S, Kenter GG, Carpenter R, Vasen HF, Thomas HJ. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma andfamilial colorectal carcinoma. Cancer 2002; 94: 1708-12
171. Thompson D, Szabo CI, Mangion J, et al. (a.o. HFA Vasen). Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21in128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci USA2002; 99: 827-31
172. Lips CJM, Griffioen G, Vasen HFA, Lamers CBHW. Muller, Weber (eds), Familiar Cancer, 1st Int. Res. Cont., Basel 1985, pp 260-262 (Karger, Basel 1985)
173. Vasen HFA, Griffioen G en Lips CJM. Erfelijk bepaalde tumoren: de zin van screening en landelijke registratie. Boerhave cursus Maag-, Darm- en Leverziekten 1986: blz. 62-66
174. Vasen HFA. Screening for Hereditary Tumours. Thesis 1989, University of Utrecht
175. Vasen HFA, Griffioen G. Familiair Colon Carcinoom. Het Medisch Jaar 1989, p 171-178
176. Vasen HFA, den Hartog Jager FCA, Menko FH, Nagengast FM, Offerhaus GJA, Griffioen G. Screening for hereditary non-polyposis colorectal cancer in the Netherlands. In: Hereditary Colorectal Cancer, J Utsunomiya, H Lynch (Eds), Springer Verlag, Tokyo, 1990
177. Griffioen G, Vasen HFA, den Hartog Jager FCA, Nagengast FM, Verspaget HW, Meera Khan P, Lamers CBHW. Value of registration in the identification and surveillance of familial adenomatous polyposis in The Netherlands. In: Hereditary Colorectal Cancer, J Utsunomiya, H Lynch (Eds), Springer Verlag, Tokyo, 1990
178. Tops CMJ, Brenkel C, Wijnen JTh van de Klift HM, van Leeuwen-Cornelisse ISJ, Vasen HFA, Griffioen G. Linkage studies on familial adenomatous polyposis in the Netherlands. In: Hereditary Colorectal Cancer, J Utsunomiya, H Lynch (Eds), Springer Verlag, Tokyo, 1990
179. Meera Khan P, Tops CMJ, Breukel C, Wijnen JTh, van der Klift HM, van Leeuwen-Cornelisse ISJ, Vasen HFA, Griffioen G, den Hartog Jager FCA, Lamers CBHW. Closely linked DNA markers for preclinical prediction of familial adenomatous polyposis. In: Familial Adenomatous Polyposis, L Herrera, AR Liss (Eds), New York, 1990: 393-396
180. Vasen HFA, Lips CJM. Strategy for an approach to familial medullary thyroid cancer Practical, psychological and genetic aspects of screening. In: Medullary Thyroid Carcinoma Ed C Calmettes, JM Guliana Colloque INSERM/John Libbey Eurotext Ltd 1991; 211: 241-243
181. Calmettes C, Hansen H, Limbert E, P Møller P, Ponder B, Raue F, Vasen H, Weissel M. Epidemiology and genetics of medullary thyroid cancer Preliminary results of an European concerted action. In: Medullary Thyroid Carcinoma Ed C Calmettes, JM Guliana Colloque INSERM/John Libbey Eurotext Ltd 1991; 211: 255-264
182. Vasen HFA, Møller Hj, Meera Khan P. DNA diagnosis in families with hereditary forms of cancer. In: Familial Cancer Control; W Weber (Ed), Springer Verlag 1992:113-116
183. Meera Khan P, van den Broek MH, Tops CMJ, Fodde R van Leeuwen Cornelisse ISJ, Griffioen G, Taal B, Menko FH, Nagengast FM, Lindhout D, Vasen HFA. Family studies in search of genes determining hereditary colorectal cancer. In: Proceedings of the 5th International Symposium on colorectal Cancer: Biology and Management of High Risk Groups, Excerpta Medica 1992; 7-13
184. Vasen HFA, Cats A, Meijer W, Griffioen G, Menko FH, Taal B, Kleibeuker J, Meera Khan P, Nagengast FM. Heterogeneity in hereditary non-polyposis colorectal cancer. In: Proceedings of the 5th International Symposium on colorectal Cancer: Biology and Management of High Risk Groups, Excerpta Medica 1992; 231-235
185. Vasen HFA. Inherited forms of colorectal cancer: Guidelines for surveillance. In: Procedures in hepatogastroenterology CJJ Mulder, GNJ Tijgat (Eds) 1993: 17
186. Watson P, Vasen HFA, Mecklin JP, Lynch HT. The risk of endometrial cancer in Hereditary Nonpolyposis Colorectal Cancer. (Am J Med 1994;96:516-520) Chosen for the Year Book of Obstretrics and Gynecology, ed Mosby Year Book Inc 1995
187. Vasen HFA, Meera Khan P. Hereditary nonpolyposis colorectal cancer: phenotype-genotype correlation and screening protocols. In: A New Strategy for Treatment of Hereditary Colorectal Cancer. ed. Baba. 1996
188. Vasen HFA. Inherited forms of colorectal cancer: guidelines for management. In: procedures in Hepatogastroenterology, eds. G.N.J. Tijtgat and C.J.J. Mulder; 1997, p. 331-337
189. Vasen HFA, de Bock G. De patient met familiaire belasting van maligniteiten: screening zonder klachten. In : cursusboek Boerhaave "Diagnostische Strategien" 1996; 87-102
190. Vasen HFA, Wijnen J, Meera Khan P, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. (Gastroenterology 1996;110:1020-1027). Chosen for the Year Book of Oncology, ed Mosby Year Book Inc. 1997
191. Menko FH, Wijnen JTh, Vasen HFA, Sijmons RH, Meera Khan P. Familial and hereditary non-polyposis colorectal cancer: issues relevant for surgical practice. In Recent results in Cancer Research, Vol 146. Springer-Verlag Berlin - Heidelberg 1998
192. Vasen HFA, Griffioen G, Wijnen J, Boonstra H, Fodde R, Meera Khan P. Surveillance and management of hereditary nonpolyposis colorectal cancer. Special Issue UICC International Union Against Cancer; Familial Cancer and Prevention. (ed. J. Utsunomiya, and W. Weber) 1999;259-267
193. Vasen HFA. Periodiek onderzoek van families met erfelijk colorectaal carcinoom. Hoofdstuk Boerhaave cursusboek: Erfelijke vormen van Kanker"; 0:ISBN-90-6767-421-4; 21 mei 1999
194. Vasen HFA, Brunner HG.: Klinisch genetische aspecten van kanker.In: Van de Velde CJH et al, editors. Oncologie, 6e druk. Houten: Bohn Stafleu Van Loghum, 2000; in press
195. Vasen HFA, de Vos W. Screening of prophylactische colectomie in HNPCC. Hoofdstuk Boerhave cursusboek: Erfelijke vormen van kanker, november 2000
196. Vasen HFA. What does genetic testing tell and doesn't tell in colorectal cancer. In: ASCO 2000 Clinical Practice Forum book (ed: MC Perry); 37-43
197. Vasen HFA. Wat is het preventieprotocol voor een dochter die een moeder heeft van veertig jaar met mammacarcinoom. In: Gynaecologie Vademecum. Bohn Stafleu van Loghum, Houten/Diegem 2000
198. Peltomaki P, Vasen H, Jass JR. In: WHO Classification of Tumours. Pathology and genetics of tumours of the digestive ract (ed. SR Hamilton, LA Aaltonen) IARC Press, Lyon 2000. Hereditary nonpolyposis colorectal cancer 126-129
199. Vasen HFA, Bröcker-Vriends A. Guidelines for the management of hereditary cancer. (ed. Stichting Opsporing Erfelijke Tumoren en de Vereniging Klinische Genetica Nederland, Werkgroep Klinische Oncogenetica) ISBN 90-806183-1-4. Leiden 2001
200. Vasen HFA, Nooy MA. Ovarian and breast cancer as part of hereditary nonpolyposis colorectal cancer(HNPCC) and other hereditary colorectal cancer syndromes. In: Familial Breast and Ovarian Cancer. Cambridge University Press. 2003